Daily Rules, Proposed Rules, and Notices of the Federal Government


Food and Drug Administration

[Docket No. FDA-2009-E-0541]

Determination of Regulatory Review Period for Purposes of Patent Extension; INVEGA SUSTENNA

AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
SUMMARY: The Food and Drug Administration (FDA) has determined the regulatory review period for INVEGA SUSTENNA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.
ADDRESSES: Submit electronic comments to Submit written petitions along with three copies and written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Beverly Friedman, Office of Regulatory Policy, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 6222,Silver Spring, MD 20993-0002, 301-796-3602.

The Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L.. 98-417) and the Generic Animal Drug and Patent Term Restoration Act (Pub. L. 100-670) generally provide that a patent may be extended for a period of up to 5 years so long as the patented item (human drug product, animal drug product, medical device, food additive, or color additive) was subject to regulatory review by FDA before the item was marketed. Under these acts, a product's regulatory review period forms the basis for determining the amount of extension an applicant may receive.

A regulatory review period consists of two periods of time: A testing phase and an approval phase. For human drug products, the testing phase begins when the exemption to permit the clinical investigations of the drug becomes effective and runs until the approval phase begins. The approval phase starts with the initial submission of an application to market the human drug product and continues until FDA grants permission to market the drug product. Although only a portion of a regulatory review period may count toward the actual amount of extension that the Director of Patents and Trademarks may award (for example, half the testing phase must be subtracted as well as any time that may have occurred before the patent was issued), FDA's determination of the length of a regulatory review period for a human drug product will include all of the testing phase and approval phase as specified in 35 U.S.C. 156(g)(1)(B).

FDA recently approved for marketing the human drug product INVEGA SUSTENNA (paliperidone palmitate). INVEGA SUSTENNA is indicated for the acute and maintenance treatment of schizophrenia in adults. Subsequent to this approval, the Patent and Trademark Office received a patent term restoration application for INVEGA SUSTENNA (U.S. Patent No. 5,254,556) from Janssen, L.P., and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration and that FDA determine the product's regulatory review period. In a letter dated June 1, 2011, FDA advised the Patent and Trademark Office that this human drug product had undergone a regulatory review period and that the approval of INVEGA SUSTENNA represented the first permitted commercial marketing or use of the product.

FDA has determined that the applicable regulatory review period for INVEGA SUSTENNA is 2,253 days. Of this time, 1,608 days occurred during the testing phase of the regulatory review period, while 645 days occurred during the approval phase. These periods of time were derived from the following dates:

1.The date an exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 355(i)) became effective:June 2, 2003. FDA has verified the applicant's claim that the date the investigational new drug application became effective was on June 2, 2003.

2.The date the application was initially submitted with respect to the human drug product under section 505(b) of the FD&C Act:October 26, 2007. FDA has verified the applicant's claim that the new drug application (NDA) for Invega Sustenna (NDA 22-264) was submitted on October 26, 2007.

3.The date the application was approved:July 31, 2009. FDA has verified the applicant's claim that NDA 22-264 was approved on July 31, 2009.

This determination of the regulatory review period establishes the maximum potential length of a patent extension. However, the U.S. Patent and Trademark Office applies several statutory limitations in its calculations of the actual period for patent extension. In its application for patent extension, this applicant seeks 1,449 days of patent term extension.

Anyone with knowledge that any of the dates as published are incorrect may submit to the Division of Dockets Management (seeADDRESSES) either electronic or written comments and ask for a redetermination by August 23, 2011. Furthermore, any interested person may petition FDA for a determination regarding whether theapplicant for extension acted with due diligence during the regulatory review period by December 21, 2011. To meet its burden, the petition must contain sufficient facts to merit an FDA investigation. (See H. Rept. 857, part 1, 98th Cong., 2d sess., pp. 41-42, 1984.) Petitions should be in the format specified in 21 CFR 10.30.

Interested persons may submit to the Division of Dockets Management (seeADDRESSES) electronic or written comments and written petitions. It is only necessary to send one set of comments. It is no longer necessary to send three copies of mailed comments. However, if you submit a written petition, you must submit three copies of the petition. Identify comments with the docket number found in brackets in the heading of this document.

Comments and petitions that have not been made publicly available onhttp://www.regulations.govmay be viewed in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

Dated:June 2, 2011. Jane A. Axelrad, Associate Director for Policy, Center for Drug Evaluation and Research.